Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Mariana C PagottiResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.ORCID 0000-0001-7295-942X
Herbert J DiasDepartment of Chemistry, Faculty of Philosophy, Sciences and Letters, University of São Paulo, Ribeirão Preto 14040-901, SP, Brazil.ORCID 0000-0001-6612-2295
Ana Carolina B B CandidoResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.ORCID 0000-0002-1431-5375
Thaís A S OliveiraDepartment of Chemistry, Faculty of Philosophy, Sciences and Letters, University of São Paulo, Ribeirão Preto 14040-901, SP, Brazil.
Alexandre BorgesResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.
Nicoli D OliveiraAnimal Science Post Graduation, University of Franca, Franca 14404-600, SP, Brazil.
Carla D LopesDepartment of Biochemistry and Immunology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Renato P OrenhaResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.ORCID 0000-0001-7285-8098
Renato L T ParreiraResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.ORCID 0000-0002-5623-9833
Antônio E M CrottiDepartment of Chemistry, Faculty of Philosophy, Sciences and Letters, University of São Paulo, Ribeirão Preto 14040-901, SP, Brazil.ORCID 0000-0002-1730-1729
Lizandra G MagalhãesResearch Group on Natural Products, Center for Research in Sciences and Technology, University of Franca, Franca 14404-600, SP, Brazil.
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo 2009/12202-1Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/11164-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/20094-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/24856-2
6 · The paper itself
Abstract
Chagas disease is a neglected tropical disease that affects more than 8 million people. Although there are therapies against this disease, the search for new drugs is important because the current treatments show limited effectiveness and high toxicity. In this work, eighteen dihydrobenzofuran-type neolignans (DBNs) and two benzofuran-type neolignans (BNs) were synthesized and evaluated against amastigote forms of two
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against · full record | OpenQuestion